Press releases - UCB
20 Nov 2024. UCB receives U.S. FDA approval for BIMZELX [®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa. Read …
Newsroom - UCB
UCB on YouTube. More videos. Resources. Access our media image selection or contact us for particular requests. View all resources. Contact. The UCB media relations team responds to …
UCB Announces Bepranemab Phase 2a Study Results Accepted for …
Oct 22, 2024 · UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting. Bepranemab - …
UCB off to a Good Start into 2024 – Progressing on its Growth …
Apr 25, 2024 · Prof. Dr. Iris Löw-Friedrich, Executive Vice President, Head of Development and UCB’s Chief Medical Officer, will be retiring from UCB. Iris is set to depart later in 2024, …
UCB and Biogen Announce Positive Topline Results From Phase 3 …
Sep 24, 2024 · UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 …
UCB - sustaining growth, now and into the future
Outlook for 2025: For the first time UCB shares its growth ambition for 2025, despite upcoming patent expirations. Based on the strong product portfolio and the promising late-stage pipeline …
UCB completes sale of established brands and updates 2024 …
Nov 5, 2024 · Successful completion of the sale of two established brands, with proceeds categorized under “other revenue”. Update of 2024 financial guidance, projecting revenue …
UCB Presents Encouraging Data on Bepranemab in Early …
Oct 31, 2024 · UCB is evaluating next steps in the development program Brussels, Belgium – 31 October 2024 – 6PM CET – UCB today reported Phase 2a data from the TOGETHER …
UCB announces U.S. FDA approval of RYSTIGGO[®] …
Jun 27, 2023 · FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult …
UCB managed 2022 headwinds and is ready for 2023 launches
UCB expects to receive initial feedback for Europe in Q1/Q2 2024. In Q4 2022, UCB initiated a Phase 2a (proof-of-concept) study to evaluate the efficacy and safety of rozanolixizumab to …